Sunday , October 17 2021

Medtech firm Ark was launched with US $ 40m Series A funding, Garage

Tue, Nov 27, 2018 – 9:00 AM


The INBOLD move for venture capital firms in the region, Singapore's Venturecraft has merged with Medtech startup Mirxes to form Ark, a cancer detection company armed with a US $ 40 million Series A investment.

The investment was led by Venturecraft shareholders and backed by Gaorong Capital (formerly Banyan Capital), one of China's top venture capital firms with a portfolio of over US $ 1.7 billion in committed investments. Venturecraft's shareholders include Alibaba's co-founder, Sun Tongyu.

Ark's goal is to eliminate late-stage cancer-related deaths within the next 30 years. The company has developed an industry-first blood test that uses micro ribonucleic acid (miRNA) as cancer markers, making the test more sensitive and robust.

The early stage detection test was developed by Mirxes, which was spun off from A * Star in 2014. Under the merger, both Mirxes and Venturecraft became the wholly owned subsidiary of Ark. Mirxes is the research and development (R & D) and manufacturing arm of the company, while Venturecraft is the corporate venture arm that will also drive marketing and commerce.

Zhou Lihan, co-founder and co-CEO of Ark, told The Business Times that by building an entire value chain, the company was able to keep the cost of the cancer detection test affordable. "For traditional technology companies that only do manufacturing or outsourcing," said Zhou, who was previously chief technology. officer of Mirxes.

"But it is our building value that means we are still profitable while making our product affordable."

Ark's first product will be a stomach cancer The blood test that detects the early stage stomach cancer before clinical symptoms appears. The Singapore Gastric Cancer Consortium, A * Star's Diagnostics Development Hub (DxD Hub), the National University Hospital and Tan Tock Seng Hospital.

Venturecraft first invested in Mirxes in 2016, pumping S $ 4 million into the startup. The company belongs to a special breed of venture capital firm called "venture builders". Besides owning stakes in startups, venture builders provide operational resources, networking opportunities and industry knowledge to grow them. Venture builders are more commonly found in the US and Europe; examples include Obvious Corp, which spun off Twitter, and Germany's Rocket Internet, which owns a stake in Zalora.

Now armed with US $ 40 million in fresh funds, Ark has a pedal with its commercialization efforts for its two key markets, Singapore and China.

Dr. Zhou said that in the next 10 days, the firm will submit the relevant documents as well as analytical and clinical performances of its products to regulators in Singapore and China. It expects a reply from Singapore's Health Sciences Authority in April or May 2019.

Ark has also already set in motion a plan to launch Asia's largest clinical study, with a goal of 50,000 participants through partnerships with local governments and medical institutions.

The funds will also be used to develop new blood tests that can detect many types of cancers, including breast, colon and colon cancers. Ark has also gone on a hiring spree, with its headcount more than doubling over 110 people in the last four months.

To fill the gaps in its value chain, the firm planning to launch the largest lab in China – in terms of throughput – for miRNA technology, said Isaac Ho, co-founder of Ark and Venturecraft. In the first phase next year, the lab will employ about 90 people.

As for Venturecraft's portfolio companies, Mr. Ho said that the firm will continue to develop startups that have products and solutions that are complementary to Ark, and exit the others.

Remaining startups in the portfolio include Reebonz, Kaleido Biosciences, e27, Glissade Dental, Attonics Systems and AIM Biotech.

Mr. Ho pointed out that the merger with Mirxes has helped to streamline the firm's investment choices and improve their strategy. In particular, early stage technology now has access to Ark's large pool of clinical resources to validate their business model and technology.

Mr. Ho described it as "not going in blind", or being at the mercy of founders. "It helps us to look at better technology that we can validate ourselves. So, we are doing due diligence for them, using our own platform," he said.

Source link